STOCK TITAN

AbCellera (NASDAQ: ABCL) shareholders back directors, auditor and Say-on-Pay

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

AbCellera Biologics Inc. reported the results of its annual shareholder meeting held on June 11, 2026. Shareholders elected Class III directors John S. Montalbano and Stephen R. Quake to terms ending at the 2029 annual meeting. As of the April 15, 2026 record date, 305,264,947 common shares were outstanding and entitled to vote.

Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers (Say-on-Pay). No other matters were submitted for a vote.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares entitled to vote 305,264,947 shares Common shares outstanding as of April 15, 2026 record date
Votes for Montalbano 141,430,732 for Election of Class III director John S. Montalbano, CFA
Votes for Quake 149,019,960 for Election of Class III director Stephen R. Quake, D.Phil.
Broker non-votes Proposal 1 36,576,359 shares Broker non-votes on director election proposal
Auditor ratification for votes 189,927,972 for Ratification of Ernst & Young LLP as 2026 auditor
Say-on-Pay for votes 142,831,950 for Advisory approval of named executive officer compensation
Say-on-Pay broker non-votes 36,576,359 shares Broker non-votes on Proposal 3
Annual Meeting of Shareholders financial
"held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2026"
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
Class III directors financial
"to elect John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors"
Class III directors are members of a company’s board assigned to one of several staggered term groups, so only that class faces election in a particular year while other classes stay in place. For investors this affects corporate control and takeover risk because staggered elections make it slower and harder for an outside group to replace a majority of directors quickly—think of it as a rotating schedule for board seats that provides continuity but can also entrench existing leadership.
independent registered public accounting firm financial
"to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding advisory basis financial
"to approve on a non-binding advisory basis, the compensation of the Company’s named executive offices"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
Say-on-Pay financial
"the compensation of the Company’s named executive offices, or Say-on-Pay (“Proposal 3”)"
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
broker non-votes financial
"The broker non-votes for this Proposal 1 totaled 36,576,359 common shares"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001703057falseVancouverBC00017030572026-06-112026-06-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 11, 2026
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue
Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 5.07    Submission of Matters to a Vote of Security Holders.
AbCellera Biologics Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 305,264,947 common shares of the Company outstanding and entitled to vote at the Annual Meeting. The Company’s shareholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2026: (i) to elect John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors of the Company to serve for a three-year term expiring at the Company’s annual meeting of shareholders in 2029 and until his or her successor has been elected and qualified (“Proposal 1”), (ii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”), and (iii) to approve on a non-binding advisory basis, the compensation of the Company’s named executive offices, or Say-on-Pay (“Proposal 3”).
Proposal 1
The Company’s shareholders approved the election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors recommended for election in Proposal 1 at the Annual Meeting. The Company’s shareholders voted for the Class III directors as follows:
NomineeForAgainstAbstain
John S. Montalbano, CFA141,430,73212,723,34245,898
Stephen R. Quake, D.Phil.149,019,9605,113,05666,956
The broker non-votes for this Proposal 1 totaled 36,576,359 common shares.


Proposal 2
The Company’s shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:

ForAgainstAbstain
189,927,972552,429295,930


Proposal 3
The Company’s shareholders approved Proposal 3. The votes cast at the Annual Meeting were as follows:

ForAgainstAbstain
142,831,95010,932,105435,917


The broker non-votes for this Proposal 3 totaled 36,576,359 common shares.

No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 12, 2026ABCELLERA BIOLOGICS INC.
 
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)

FAQ

What did AbCellera Biologics Inc. (ABCL) shareholders vote on at the 2026 annual meeting?

Shareholders voted on electing two Class III directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving Say-on-Pay compensation for named executive officers. All three proposals received shareholder approval at the June 11, 2026 meeting.

Who was elected to AbCellera Biologics Inc. (ABCL) board at the 2026 annual meeting?

Shareholders elected John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors. They will serve three-year terms expiring at the 2029 annual meeting, continuing in office until their successors are elected and qualified.

How many AbCellera (ABCL) shares were entitled to vote at the 2026 annual meeting?

As of April 15, 2026, the record date, 305,264,947 common shares were outstanding and entitled to vote. This share count determined which shareholders could participate in decisions on director elections, auditor ratification, and Say-on-Pay approval.

Did AbCellera (ABCL) shareholders approve the company’s auditor for 2026?

Yes. Shareholders ratified the appointment of Ernst & Young LLP as AbCellera’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes on this proposal were reported as 189,927,972 for, 552,429 against, and 295,930 abstaining.

Was AbCellera Biologics Inc. (ABCL) Say-on-Pay proposal approved in 2026?

Yes. The non-binding advisory Say-on-Pay proposal on named executive officer compensation was approved. Votes were 142,831,950 for, 10,932,105 against, and 435,917 abstaining, with 36,576,359 broker non-votes reported for this proposal.

Were there any other matters voted on at AbCellera (ABCL) 2026 annual meeting?

No. The company reported that no other matters were submitted to, or voted on by, shareholders at the annual meeting beyond director elections, auditor ratification, and the advisory Say-on-Pay proposal.

Filing Exhibits & Attachments

3 documents